Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio (Nasdaq: VOR), a clinical-stage company focusing on cell and genome engineering, will participate in several investor conferences. The Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, at 9:30 am ET in New York. A fireside chat at the 5th Annual Evercore ISI HealthCONx Virtual Conference will occur on December 1 at 3:05 pm ET, followed by another fireside chat at The JMP Securities Hematology and Oncology Virtual Summit on December 6 at 1:20 pm ET. Webcasts of these events will be available on their website.
- None.
- None.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Piper Sandler 34th Annual Healthcare Conference
Presentation: Tuesday, November 29, 2022 at 9:30 am ET
Location: Lotte New York Palace Hotel, New York, NY
5th Annual Evercore ISI HealthCONx Virtual Conference
Fireside chat: Thursday, December 1 at 3:05 pm ET
The JMP Securities Hematology and Oncology Virtual Summit
Fireside chat: Tuesday, December 6, 2022 at 1:20 pm ET
A live webcast and archived replay of the presentation and fireside chats will be available on the investors section of our website, linked here: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
When will Vor Bio participate in the Piper Sandler Healthcare Conference?
What is the date of Vor Bio's fireside chat at the Evercore ISI HealthCONx Conference?
When is the JMP Securities Hematology and Oncology Virtual Summit featuring Vor Bio?
Where can I find the webcasts for Vor Bio's investor presentations?